ASX Announcement

Retirement of Lesley Russell as Non-Executive Director, Committee Changes

Sydney, Australia, 11 November 2026: Imugene Limited (ASX: IMU) ("Imugene" or "the Company"), a clinical-stage cellular therapy company, announces that further to today's Annual General Meeting (AGM), Dr Lesley Russell has resigned as a Non-Executive Director of the Company, effective immediately.

Dr Russell joined the Board in April 2019 and has been a valued leader of the Company since that time.

Imugene Chair, Mr Paul Hopper, said: "On behalf of the Board, management and shareholders, I thank Lesley for her wisdom, service and contribution since joining the Board in 2019. Her guidance has been invaluable to Imugene, and we wish her every success in the future."

Following Dr Russell's resignation, and effective 11 November 2026, the Audit and Risk Committee will comprise Ms Kim Drapkin, Mr Michael Kotsanis and Mr Jakob Dupont, with Ms Drapkin continuing as Chair of the Committee. The Remuneration and Nomination Committee will comprise Mr Michael Kotsanis (Committee Chair), Dr Charmaine Gittleson and Ms Kim Drapkin. Both Committees are comprised of majority independent directors and are chaired by independent directors.

Dr Russell's final Director's Interest Notice (Appendix 3Z) will be lodged separately.

For more information please contact:

General Investor Enquiries
shareholderenquiries@imugene.com

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

About Imugene (ASX: IMU)

Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Imugene is focused on developing azer-cel for patients with B-cell cancers whose disease has progressed on existing treatments, including CAR T and BTK inhibitors.

Release authorised by the Executive Chairman, Imugene Limited.